LOW-DOSE GAMMA-INTERFERON THERAPY IS INEFFECTIVE IN RENAL-CELL CARCINOMA PATIENTS WITH LARGE TUMOR BURDEN

被引:13
作者
AULITZKY, WE
LERCHE, J
THEWS, A
LUTTICHAU, I
JACOBI, N
HEROLD, M
AULITZKY, W
PESCHEL, C
STOCKLE, M
STEINBACH, F
HUBER, C
机构
[1] GEN HOSP SALZBURG, DEPT UROL, SALZBURG, AUSTRIA
[2] UNIV MAINZ, SCH MED, DEPT INTERNAL MED 3, DIV HEMATOL, W-6500 MAINZ, GERMANY
[3] UNIV MAINZ, SCH MED, DEPT UROL, W-6500 MAINZ, GERMANY
[4] UNIV INNSBRUCK, SCH MED, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA
关键词
D O I
10.1016/0959-8049(94)90119-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The efficacy and immunomodulatory effects of low-dose gamma-interferon (gamma IFN) were investigated in an unselected population of patients with metastasising renal cell carcinoma. 36 patients suffering from metastasising renal cell carcinoma with a performance status exceeding Karnofsky index of 50 were entered into the open phase I/II trial. The majority of the patients recruited displayed a large tumour burden, and 28 patients (78%) had metastases involving two to six organ sites. Treatment was started with a 2-week cycle of either daily or weekly subcutaneous administration of either 100, 200 or 400 mu g gamma IFN. After a therapy-free interval of 2 weeks treatment was switched to the alternate mode of administration. Subsequently, treatment was continued with the same dose applied once a week for a minimum of 3 months. Serum levels of neopterin and beta-2-microglobulin, as well as how cytometric analyses of peripheral blood mononuclear cells, were used for the assessment of biological response. Minimal antitumour activity was observed in this high-risk patient group and only 1 patient experienced a partial response (PR) lasting 36+ months. Comparison of the patients' characteristics to those of other low-dose gamma IFN trials revealed a highly significant difference in the tumour burden and clinical response. We conclude that patient selection is a decisive parameter for the outcome of treatment with low-dose gamma IFN, and that patients with poor prognostic features and a large tumour burden are not likely to respond to this almost atoxic treatment.
引用
收藏
页码:940 / 945
页数:6
相关论文
共 25 条
[11]  
2-#
[12]   THE DETERMINATION OF AN IMMUNOLOGICALLY ACTIVE DOSE OF INTERFERON-GAMMA IN PATIENTS WITH MELANOMA [J].
MALUISH, AE ;
URBA, WJ ;
LONGO, DL ;
OVERTON, WR ;
COGGIN, D ;
CRISP, ER ;
WILLIAMS, R ;
SHERWIN, SA ;
GORDON, K ;
STEIS, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :434-445
[13]  
MUSS HB, 1988, SEMIN ONCOL, V15, P30
[14]   UNEXPLAINED SPONTANEOUS REGRESSION AND ALPHA-INTERFERON AS TREATMENT FOR METASTATIC RENAL-CARCINOMA [J].
OLIVER, RTD ;
NETHERSELL, ABW ;
BOTTOMLEY, JM .
BRITISH JOURNAL OF UROLOGY, 1989, 63 (02) :128-131
[15]   CONTINUOUS INFUSION OF RECOMBINANT INTERLEUKIN-2 WITH OR WITHOUT AUTOLOGOUS LYMPHOKINE ACTIVATED KILLER-CELLS FOR THE TREATMENT OF ADVANCED RENAL-CELL CARCINOMA [J].
PALMER, PA ;
VINKE, J ;
EVERS, P ;
POURREAU, C ;
OSKAM, R ;
ROEST, G ;
VLEMS, F ;
BECKER, L ;
LORIAUX, E ;
FRANKS, CR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (6-7) :1038-1044
[16]   PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA TREATED WITH RECOMBINANT INTERLEUKIN-2 [J].
PALMER, PA ;
VINKE, J ;
PHILIP, T ;
NEGRIER, S ;
ATZOPODIEN, J ;
KIRCHNER, H ;
OSKAM, R ;
FRANKS, CR .
ANNALS OF ONCOLOGY, 1992, 3 (06) :475-480
[17]   CLINICAL TOXICITY OF INTERFERONS IN CANCER-PATIENTS - A REVIEW [J].
QUESADA, JR ;
TALPAZ, M ;
RIOS, A ;
KURZROCK, R ;
GUTTERMAN, JU .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :234-243
[18]   OBSERVATIONS ON THE SYSTEMIC ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 TO PATIENTS WITH METASTATIC CANCER [J].
ROSENBERG, SA ;
LOTZE, MT ;
MUUL, LM ;
LEITMAN, S ;
CHANG, AE ;
ETTINGHAUSEN, SE ;
MATORY, YL ;
SKIBBER, JM ;
SHILONI, E ;
VETTO, JT ;
SEIPP, CA ;
SIMPSON, C ;
REICHERT, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (23) :1485-1492
[19]   INTERLEUKIN-2 BOLUS THERAPY INDUCES IMMEDIATE AND SELECTIVE DISAPPEARANCE FROM PERIPHERAL-BLOOD OF ALL LYMPHOCYTE SUBPOPULATIONS DISPLAYING NATURAL-KILLER ACTIVITY - ROLE OF CELL-ADHESION TO ENDOTHELIUM [J].
SALVO, G ;
SAMOGGIA, P ;
MASCIULLI, R ;
BOCCOLI, G ;
ALLAVENA, P ;
MARIANI, G ;
BULLO, A ;
MONTESORO, E ;
BULGARINI, D ;
CARLINI, P ;
RUGGERI, EM ;
ARENA, MG ;
CAMAGNA, A ;
TESTA, U ;
CALABRESI, F ;
PESCHLE, C .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :818-825
[20]   INTERLEUKIN-2 TOXICITY [J].
SIEGEL, JP ;
PURI, RK .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :694-704